|drug562||CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) Wiki||0.38|
|drug4008||placebo rinse Wiki||0.38|
|drug2734||Questionnaire by phone call Wiki||0.38|
|drug2641||PrimePro™/ PrimeMSK™ Wiki||0.38|
|drug567||CLIA of IgG and IgM against SARS-Cov-2 Wiki||0.38|
|drug3117||Skin biopsy Wiki||0.38|
|drug3412||Throat swab Wiki||0.27|
|drug491||Blood sampling Wiki||0.27|
|D012859||Sjogren's Syndrome NIH||0.44|
|D012213||Rheumatic Fever NIH||0.44|
|D009140||Musculoskeletal Diseases NIH||0.38|
|D048909||Diabetes Complications NIH||0.38|
|D019636||Neurodegenerative Diseases NIH||0.38|
|D008180||Lupus Erythematosus, Systemic NIH||0.31|
|D012871||Skin Diseases NIH||0.27|
|D012216||Rheumatic Diseases NIH||0.23|
|D011111||Polymyalgia Rheumatica NIH||0.22|
|D013700||Giant Cell Arteritis NIH||0.22|
|D015535||Arthritis, Psoriatic NIH||0.19|
|D009422||Nervous System Diseases NIH||0.17|
|D003095||Collagen Diseases NIH||0.13|
|D001172||Arthritis, Rheumatoid NIH||0.11|
|D008171||Lung Diseases, NIH||0.08|
|D002318||Cardiovascular Diseases NIH||0.06|
|D018352||Coronavirus Infections NIH||0.01|
There are 7 clinical trials
This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.
Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.Measure: Adjusted Odds Ratio Time: 4 months after inclusion
Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.
The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.
Description: ELISA tests for COVID-19 antibodiesMeasure: COVID-19 seroconversion Time: 1 day, during routine blood collection
Description: Case report form filled by the health professionalMeasure: COVID-19 infection Time: During medical visit or phone consultation, up to 2 hours
Description: Descriptive analysis for each disease's rateMeasure: Seroconversion rate by disease Time: 1 day, during routine blood collection
Description: Descriptive analysis for each country's rateMeasure: Penetration across Europe Time: 1 day, during routine blood collection
Description: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.Measure: COVID-19 severity Time: During medical visit, up to 1 hour
Description: Descriptive analysis for overall and COVID-19-linked mortality ratesMeasure: COVID-19 mortality rate Time: During contact with family members, up to 1 hour
Description: Case report form filled by the health professionalMeasure: COVID-19 impact on immunomodulatory treatment Time: During medical visit, up to 1 hour
Description: Case report form filled by the patientMeasure: Patient-reported flares Time: During medical visit, up to 1 hour
Description: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.Measure: Patient's fears towards COVID-19 Time: During medical visit, up to 1 hour
Description: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.Measure: Patient's beliefs in their medicines towards COVID-19 Time: During medical visit, up to 1 hour
this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients suffering from inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases. The objective of the study is to compare RMD patients with COVID 19 infection (cases) to RMD patients who have not had COVID 19 infection (controls) on their mental health.
The study explore the relationship between COVID-19 and the induction of autoimmune diseases.
Description: incidence of autoimmune conditionsMeasure: incidence of autoimmune conditions Time: Two-weeks
This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.
Description: General Health Outcome Instrument used to derive a simple psychometric score for health related quality of life which provides scores on various dimensions or items describing the systems. The score is derived by adding the unweighted response order of each question, with a lower score denoting a better quality of life.Measure: Assessment of quality of life (QOL) via 36-Item Short Form Survey (SF-36) change from baseline at 6 and 12 months. Time: Follow up time-frames will measure changes occurring from baseline post procedure at 6 months and 12 months.
Description: Upper Extremity Outcome InstrumentMeasure: Assessment of disabilities of arm, shoulder, hand via DASH Questionnaire change from baseline at 6 and 12 months. Time: Follow up time-frames will measure changes occurring from baseline post procedure at 6 months and 12 months.
Description: Erectile Function Questionnaire. Scoring exists from 0 to 25. The lower the score, the more severe the Erectile Dysfunction.Measure: Assessment of erectile function via International Index of Erectile Function (IIEF-5) change from baseline at 6 and 12 months. Time: Follow up time-frames will measure changes occurring from baseline post procedure at 6 months and 12 months.
Description: COPD Outcome Instrument. Items are scored on a Likert scale (range 0-60). Higher scores indicate a worse health status.Measure: Assessment of COPD via Clinical Chronic Obstructive Pulmonary Disease Questionnaire change from baseline at 6 and 12 months. Time: Follow up time-frames will measure changes occurring from baseline post procedure at 6 months and 12 months.
Description: Memory Outcome Instrument. The maximum MMSE score is 30 points. The lower the score, the more severe the dementia.Measure: Assessment of mental state via Mini Mental State Examination (MMSE) change from baseline at 6 and 12 months. Time: Follow up time-frames will measure changes occurring from baseline post procedure at 6 months and 12 months.
Description: Voiding and Pain Indices. Possible score of 0-20 with higher scores denoting better function.Measure: Assessment of interstitial cystitis via O'Leary/Sant Questionnaire change from baseline at 6 and 12 months. Time: Follow up time-frames will measure changes occurring from baseline post procedure at 6 months and 12 months.
Description: Low Back Pain Outcome Instrument. Possible score of 0-100 with lower scores denoting better function.Measure: Assessment of back pain via Oswestry Low Back Pain Disability Questionnaire change from baseline at 6 and 12 months. Time: Follow up time-frames will measure changes occurring from baseline post procedure at 6 months and 12 months.
Description: Arthritis Outcome Instrument. Individual question scores are then summed to form a raw score ranging from 0 (worst) to 96 (best)Measure: Assessment of osteoarthritis via Western Ontario and McMaster Osteoarthritis Index (WOMAC) change from baseline at 6 and 12 months. Time: Follow up time-frames will measure changes occurring from baseline post procedure at 6 months and 12 months.
Background: Viral infections such as COVID-19 may lead to flare-ups in people with systemic autoimmune diseases (SAD). These infections may also change the function of their immune system and/or cause problems with their blood vessels. Researchers want to learn how people with SAD respond to treatments or vaccines for COVID-19. Objective: To understand how COVID-19 affects inflammation, the immune system, and blood vessels in adults and children with autoimmune diseases. Eligibility: People ages 15 and older who have been diagnosed with an autoimmune disease or are a healthy volunteer Design: Participants will have a screening visit. This will include: Medical history and physical exam EKG Chest x-ray COVID-19 test. A swab will be put in the participant s nose or the back of their mouth. Blood and urine tests Participants will be placed into 1 of 4 groups: 1. Those with previously documented COVID-19 infection or COVID vaccination 2. Those with a recently known COVID-19 exposure or vaccination 3. Those with no known COVID-19 exposure or vaccination 4. Those who developed an acute COVID-19 infection Depending on their group, participants will have 1 to 5 more visits. These will occur over 12 to 18 months. Visits may include: FDG PET/CT scan. Participants will lie in a doughnut-shaped machine. The machine creates pictures of the body. For the scan, they will have a radioactive substance injected into their arm through an IV. Kidney function tests Non-invasive vascular studies test. These tests are similar to what it feels like to have blood pressure checked.
Description: Measures of Immune dysregulation (gene expression changes in immune cells, immune cell subset proportions, serum cytokine and autoantibody levels and repertoire), vasculopathy (changes in vascular function tests (CAVI, Endopat and sphygmocor quantification) and , in some cases, vascular inflammation (as measured by FDG-PET CT) before and after COVID-19.Measure: Primary Objective: Characterize how COVID-19 modulates systemic inflammation, autoimmunity features, organ damage and vasculopathy in adult and pediatric patients with a previous diagnosis of systemic autoimmunity. Assess how subjects with syste... Time: 36 months
Description: Clinical outcomes, as assessed by disease-specific activity/severity measures in response to COVID infection. Response to potential antiviral treatments and/or vaccines that are used for clinical reasons in response to COVID-19 exposure or prevention.Measure: Understand prevalence and severity of COVID-19 in individuals with autoimmune diseases, and the variables that associate/predict these responses. Time: 36 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports